重组人脑利钠肽治疗急性心力衰竭的疗效分析

目的研究观察重组人脑利钠肽(rhBNP)治疗急性心力衰竭的疗效。方法选取2011年12月至2013年3月期间我院收治的185例急性心力衰竭的患者,将其随机分为实验组(95例)与对照组(90例)。所有患者均依据急性心力衰竭诊断和治疗指南进行诊断和治疗,其中实验组在对照组的基础上加用重组人脑利钠肽进行治疗,比较两组患者治疗时间和治疗效果等指标。结果实验组患者住院时间少于对照组,而治疗效果优于对照组,差异具有统计学意义(P<0.05)。结论重组人脑利钠肽的应用可以有效提高急性心力衰竭的治疗效果,减少治疗时间,应大力推广使用。

Curative Effect Analysis of Recombinant Human Brain Natriuretic Peptide in the Treatment of Acute Heart Failure

Objective To study the effect of recombinant human brain natriuretic peptide （rhBNP） in the treatment of patients with acute heart failure. Methods 185 cases of patients with acute heart failure treated in our hospital from December 2011 to March 2013 were retrospectively analysed and randomly divided into experimental group （95 cases） and control group （90 cases）. All the patients were dignosed and treated according to the guide of the dignosis and treatment of acute heart failure, the experimental group received recombinant human brain natriuretic peptide on the basis of control group, the time and treatment effect of the two groups was compared. Results The hospitalization time of the experimental group was shorter than that of the control group, and the treatment effect of the experimental group was better than those of the control group, with statistical significant difference （P 〈0.05）. Conclusions The application of recombinant human brain natriuretic peptide can effectively improve the treatment effect of acute heart failure and reduce the treatment time, which is wrothy of application and promotion.